Penumbra
PEN
Market cap $9.84B

254.21 USD

+27.06

11.91%

At close Jul 30, 4:00 PM EDT

After hours

254.21

+0.00

0.00%

1 day

11.91%

5 days

8.90%

1 month

-0.94%

3 months

-13.19%

6 months

-5.50%

Year to date

5.93%

1 year

46.87%

5 years

13.22%

10 years

515.52%

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Employees: 4,500

Healthcare Medical Devices

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

502% more call options, than puts

Call options by funds: $95.8M | Put options by funds: $15.9M

138% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 39

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]

13% more funds holding

Funds holding: 367 [Q4 2024] → 416 (+49) [Q1 2025]

11% more capital invested

Capital invested by funds: $8.3B [Q4 2024] → $9.24B (+$946M) [Q1 2025]

9% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 129

1.27% less ownership

Funds ownership: 90.97% [Q4 2024] → 89.7% (-1.27%) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$285

12%

upside

Avg. target

$311

23%

upside

High target

$350

38%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

Truist Securities David Rescott	22%upside $310	Buy Maintained	30 Jul 2025
UBS Priya Sachdeva	32%upside $335	Buy Maintained	30 Jul 2025
RBC Capital Shagun Singh	28%upside $325	Outperform Maintained	30 Jul 2025
Baird David Rescott	12%upside $285	Outperform Maintained	30 Jul 2025
Wells Fargo Larry Biegelsen	14%upside $290	Overweight Maintained	30 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about PEN published over the past 30 days

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

ALAMEDA, Calif. , July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

The Motley Fool

Penumbra (PEN) Q2 Revenue Jumps 13%

Penumbra (PEN) Q2 Revenue Jumps 13%

Penumbra (PEN) Q2 Revenue Jumps 13%

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Adam Elsesser - Co-Founder, Chairman, President & CEO Cecilia Furlong - Corporate Participant Jason Richard Mills - Executive Vice President of Strategy Maggie S. Yuen - Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

Penumbra (PEN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.64 per share a year ago.

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

ALAMEDA, Calif. , July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025.

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

Zacks Investment Research

ITGR vs. PEN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?

ITGR vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research

Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report?

Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report?

Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House.

Five years after COVID, pharma shares languish in US policy limbo

Zacks Investment Research

Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth

See News Rankings

Charts implemented using Lightweight Charts™